Menu

Question 1581

Topic: Biology, Genetics & Bone Healing

A 70-year-old woman is prescribed denosumab for the treatment of severe postmenopausal osteoporosis. Which of the following best describes the exact molecular mechanism of action of this pharmacological agent?

. It directly binds to osteoprotegerin (OPG), preventing the inhibition of osteoclastogenesis
. It directly binds to RANK ligand (RANKL), preventing its interaction with the RANK receptor on osteoclasts
. It acts as a decoy receptor binding directly to the RANK receptor, blocking physiological ligand binding
. It selectively inhibits Cathepsin K inside the ruffled border of active osteoclasts
. It binds to Sclerostin, releasing the inhibition of the Wnt signaling pathway

Correct Answer & Explanation

. It directly binds to osteoprotegerin (OPG), preventing the inhibition of osteoclastogenesis


Explanation

Denosumab is a fully human monoclonal antibody designed to mimic the physiological effects of osteoprotegerin (OPG). It specifically binds to Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). By neutralizing RANKL, it prevents RANKL from binding to the RANK receptor situated on the surface of osteoclasts and their precursors. This blockade dramatically reduces osteoclast differentiation, function, and survival, leading to decreased bone resorption. Romosozumab binds to Sclerostin, and Odanacatib (investigational) inhibits Cathepsin K.

Question 1582

Topic: Biology, Genetics & Bone Healing

Recombinant human bone morphogenetic protein-2 (rhBMP-2) is utilized in complex spine fusion surgery to induce osteoinduction. Bone morphogenetic proteins are potent growth factors belonging to the transforming growth factor-beta (TGF-ฮฒ) superfamily. Which of the following best describes the principal intracellular signaling cascade directly activated following BMP binding to its specific cellular receptor?

. JAK-STAT pathway
. Wnt/ฮฒ-catenin pathway
. Smad 1/5/8 pathway
. cAMP-Protein Kinase A pathway
. Notch-Hes pathway

Correct Answer & Explanation

. JAK-STAT pathway


Explanation

Bone Morphogenetic Proteins (BMPs) bind to cell surface type I and type II serine/threonine kinase receptors. Receptor binding induces cross-phosphorylation, which directly activates the intracellular canonical Smad signaling cascade. Specifically, for osteogenic BMPs like BMP-2, the activated receptors phosphorylate the receptor-regulated Smads (R-Smads): Smad 1, Smad 5, and Smad 8. These phosphorylated Smads then bind to the common-partner Smad (Co-Smad), Smad 4, and the entire complex translocates into the nucleus to act as transcription factors for osteogenic genes (like Runx2).

Question 1583

Topic: Biology, Genetics & Bone Healing

A 45-year-old patient requires a bone graft for a highly comminuted tibial nonunion. The surgeon chooses a graft that provides a structural physical scaffold for host osteogenic cells to migrate into, but the graft itself lacks living cells and does not contain intrinsic growth factors to stimulate stem cell differentiation. Which of the following best describes this graft's primary property and a classic example?

. Osteogenesis; autologous iliac crest bone graft
. Osteoinduction; demineralized bone matrix (DBM)
. Osteoconduction; cancellous allograft
. Osteoinduction; bone morphogenetic protein-2 (BMP-2)
. Osteoconduction; vascularized fibula autograft

Correct Answer & Explanation

. Osteogenesis; autologous iliac crest bone graft


Explanation

Osteoconduction refers to the provision of a passive structural scaffold (matrix) for host osteoprogenitor cells and blood vessels to migrate into and form new bone. Cancellous allografts and synthetic ceramics are primarily osteoconductive. Osteogenesis requires the presence of living, viable osteoprogenitor cells capable of forming new bone (e.g., fresh autograft). Osteoinduction is the stimulation of host mesenchymal stem cells to differentiate into osteoblasts, primarily mediated by growth factors such as bone morphogenetic proteins (BMPs); DBM and recombinant BMP-2 are osteoinductive.

Question 1584

Topic: Biology, Genetics & Bone Healing

A 70-year-old woman is treated with alendronate for postmenopausal osteoporosis. Bisphosphonates primarily reduce fracture risk by decreasing bone turnover. What is the precise molecular mechanism by which nitrogen-containing bisphosphonates inhibit osteoclast function?

. Direct inhibition of RANKL binding to RANK
. Inhibition of farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway
. Direct competitive inhibition of cathepsin K
. Binding to and neutralizing circulating sclerostin
. Downregulation of osteoprotegerin (OPG) expression

Correct Answer & Explanation

. Direct inhibition of RANKL binding to RANK


Explanation

Nitrogen-containing bisphosphonates (e.g., alendronate, zoledronate, risedronate) inhibit bone resorption by inhibiting farnesyl pyrophosphate (FPP) synthase, a key enzyme in the mevalonate pathway. This prevents the prenylation of small regulatory GTPases (like Ras, Rho, Rac) essential for normal osteoclast function, cytoskeletal arrangement (ruffled border formation), and cell survival, ultimately inducing osteoclast apoptosis. Denosumab inhibits RANKL. Odanacatib inhibits cathepsin K. Romosozumab binds sclerostin.

Question 1585

Topic: Biology, Genetics & Bone Healing

A 35-year-old man presents with knee pain. Radiographs demonstrate an eccentric, lytic lesion extending into the epiphysis of the distal femur. Biopsy confirms a giant cell tumor of bone. Neoadjuvant treatment with denosumab is planned. What is the mechanism of action of this medication?

. Inhibition of the tyrosine kinase receptor
. Direct apoptosis of the multinucleated giant cells
. Binding to and neutralizing RANKL
. Competitive inhibition of the vascular endothelial growth factor (VEGF) receptor
. Cross-linking of DNA leading to cell cycle arrest

Correct Answer & Explanation

. Inhibition of the tyrosine kinase receptor


Explanation

Denosumab is a human monoclonal antibody that binds to Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), thereby preventing it from activating RANK. In Giant Cell Tumor (GCT) of bone, the neoplastic mononuclear stromal cells express RANKL, which recruits and activates the osteoclast-like multinucleated giant cells that cause bone destruction. Denosumab inhibits this process.

Question 1586

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with knee pain. Radiographs reveal an eccentric, lytic epiphyseal lesion in the proximal tibia extending to the subchondral bone. Biopsy demonstrates numerous multinucleated giant cells in a background of mononuclear stromal cells. If medical therapy is considered to downstage this unresectable tumor, what is the mechanism of action of the most appropriate targeted agent?

. Inhibition of tyrosine kinase activity
. Monoclonal antibody against RANK ligand
. Inhibition of osteoclast proton pumps
. Direct cytotoxicity to mononuclear stromal cells
. Selective estrogen receptor modulation

Correct Answer & Explanation

. Inhibition of tyrosine kinase activity


Explanation

The lesion described is a giant cell tumor (GCT) of bone. Denosumab is frequently used for unresectable or metastatic GCTs, or to downstage tumors before surgery. Denosumab is a fully human monoclonal antibody that binds to RANKL, preventing it from activating RANK on the surface of osteoclasts and their precursors, thereby inhibiting osteoclast-mediated bone destruction. In GCT, the neoplastic mononuclear stromal cells express RANKL, which recruits the non-neoplastic multinucleated giant cells (osteoclasts) that cause bone lysis.

Question 1587

Topic: Biology, Genetics & Bone Healing

A 45-year-old man undergoes open reduction and internal fixation of a transverse radial shaft fracture using absolute stability techniques with a dynamic compression plate. Six weeks postoperatively, radiographs show a well-reduced fracture with no visible callus formation. Which of the following is the predominant mechanism of bone healing occurring in this scenario?

. Endochondral ossification
. Intramembranous ossification
. Primary bone healing via cutting cones
. Gap healing with initial fibrous tissue formation
. Secondary bone healing

Correct Answer & Explanation

. Endochondral ossification


Explanation

When absolute stability is achieved (e.g., with compression plating) and the fracture gap is minimal, primary bone healing occurs. This process bypasses callus formation. Instead, osteoclasts at the head of cutting cones cross the fracture site, followed closely by osteoblasts that lay down new lamellar bone (Haversian remodeling). Endochondral ossification is the hallmark of secondary bone healing, which involves a cartilaginous intermediate and callus formation, typical of non-rigid fixation (e.g., intramedullary nailing or cast immobilization).

Question 1588

Topic: Biology, Genetics & Bone Healing

A 65-year-old man presents with severe back pain and fatigue. Radiographs demonstrate multiple punched-out lytic lesions in his skull and vertebral bodies. Laboratory studies show hypercalcemia, an elevated serum creatinine, and an abnormal M-spike on serum protein electrophoresis. A bone marrow biopsy reveals sheets of plasma cells. Which of the following is the most appropriate initial medical management directly targeting his skeletal disease?

. High-dose systemic methotrexate
. Intravenous bisphosphonates
. Subcutaneous teriparatide
. Recombinant BMP-2 injections
. Broad-spectrum antibiotics

Correct Answer & Explanation

. High-dose systemic methotrexate


Explanation

The patient has multiple myeloma, characterized by the CRAB criteria (HyperCalcemia, Renal failure, Anemia, Bone lesions). The bony destruction in multiple myeloma is heavily mediated by increased osteoclast activity stimulated by RANKL and MIP-1 alpha produced by myeloma cells. Intravenous bisphosphonates (like zoledronic acid) are the standard of care to reduce skeletal-related events (SREs), treat hypercalcemia, and directly inhibit osteoclast-mediated bone resorption. Teriparatide is contraindicated in patients with an active bone malignancy.

Question 1589

Topic: Biology, Genetics & Bone Healing

Osteoclasts resorb bone by secreting hydrogen ions and proteolytic enzymes into the sealed Howship's lacuna. Which enzyme plays a critical role in the generation of the intracellular hydrogen ions necessary for this process?

. Cathepsin K
. Carbonic anhydrase II
. Matrix metalloproteinase-9
. Tartrate-resistant acid phosphatase
. Alkaline phosphatase

Correct Answer & Explanation

. Cathepsin K


Explanation

Osteoclasts produce hydrogen ions intracellularly through the action of carbonic anhydrase II, which catalyzes the hydration of carbon dioxide to form carbonic acid, which then dissociates into protons (H+) and bicarbonate. The protons are actively pumped into the resorption pit via a V-type H+-ATPase. Cathepsin K is a protease responsible for degrading the organic bone matrix (collagen) once it is demineralized. Mutations in carbonic anhydrase II cause osteopetrosis with renal tubular acidosis.

Question 1590

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a painful mass in the distal radius. Radiographs reveal an eccentrically located, purely lytic lesion in the epiphysis extending to the subchondral bone. A biopsy demonstrates multinucleated giant cells in a stroma of mononuclear cells. Treatment with denosumab is considered. What is the specific cellular or molecular target of denosumab in the treatment of this condition?

. The multinucleated giant cells
. The RANK receptor on the osteoclast precursors
. The RANK ligand produced by the neoplastic mononuclear stromal cells
. Osteoprotegerin
. Vascular endothelial growth factor (VEGF)

Correct Answer & Explanation

. The multinucleated giant cells


Explanation

Giant cell tumor of bone (GCTB) is characterized by neoplastic mononuclear stromal cells that express high levels of RANK Ligand (RANKL). This overproduction of RANKL recruits and activates normal osteoclast precursors to form the characteristic multinucleated giant cells, leading to aggressive bone resorption. Denosumab is a monoclonal antibody that specifically binds to RANKL, preventing it from interacting with the RANK receptor on osteoclasts and their precursors, thereby halting bone destruction.

Question 1591

Topic: Biology, Genetics & Bone Healing

A 34-year-old woman presents with knee pain. Radiographs reveal an eccentric, purely lytic lesion in the distal femur extending to the subchondral bone without a sclerotic rim. Biopsy confirms a giant cell tumor of bone. Due to extensive joint involvement and a high risk of morbidity with immediate curettage, neoadjuvant pharmacological therapy is planned to consolidate the lesion prior to joint-salvage surgery. Which of the following describes the mechanism of action of the most appropriate medical therapy?

. Inhibition of vascular endothelial growth factor (VEGF) receptors
. Binding to and competitive inhibition of the RANK ligand (RANKL)
. Inhibition of the mammalian target of rapamycin (mTOR) pathway
. Cross-linking of DNA double strands to prevent cellular replication
. Selective modulation of estrogen receptors (SERM) on osteoclasts

Correct Answer & Explanation

. Inhibition of vascular endothelial growth factor (VEGF) receptors


Explanation

The diagnosis is a giant cell tumor (GCT) of bone, which typically presents in young adults as an eccentric, lytic epiphyseal/metaphyseal lesion. The neoplastic stromal cells in GCT express high levels of RANKL, which recruits and activates the multinucleated giant cells (osteoclast-like cells) responsible for the aggressive osteolysis. Denosumab is a human monoclonal antibody that specifically binds to and inhibits RANKL, thereby halting osteoclastogenesis and reducing osteolysis. It is highly effective as a neoadjuvant therapy in advanced GCTs to induce a thick peripheral rim of bone, facilitating joint-salvage procedures such as extended curettage.

Question 1592

Topic: Biology, Genetics & Bone Healing

A 45-year-old patient undergoes a posterolateral spinal fusion. Demineralized bone matrix (DBM) is used as an adjunct to local autograft. DBM primarily relies on which of the following mechanisms to promote bone formation?

. Osteogenesis
. Osteoinduction
. Osteoconduction
. Osteointegration
. Creeping substitution

Correct Answer & Explanation

. Osteogenesis


Explanation

Demineralized bone matrix (DBM) is primarily an osteoinductive and osteoconductive material. The decalcification process exposes bone morphogenetic proteins (BMPs) and other growth factors, which induce local mesenchymal stem cells to differentiate into osteoblastsโ€”a process known as osteoinduction. It lacks live cells, so it is not osteogenic.

Question 1593

Topic: Biology, Genetics & Bone Healing

In the process of normal bone remodeling, osteoblast lineage cells regulate the activity of osteoclasts. Which of the following molecules acts as a soluble decoy receptor to inhibit osteoclast differentiation and activation?

. Osteoprotegerin (OPG)
. Sclerostin
. Macrophage colony-stimulating factor (M-CSF)
. Calcitonin
. Osteocalcin

Correct Answer & Explanation

. Osteoprotegerin (OPG)


Explanation

Osteoprotegerin (OPG) is secreted by osteoblasts and binds to RANKL, preventing it from interacting with RANK on the surface of osteoclast precursors. This inhibits osteoclastogenesis and reduces bone resorption. PTH and other factors can stimulate bone resorption by decreasing OPG and increasing RANKL expression.

Question 1594

Topic: Biology, Genetics & Bone Healing

A 32-year-old man sustains a comminuted midshaft femur fracture, which is stabilized with a reamed intramedullary nail. Which of the following mechanical environments is primarily provided by this construct, promoting secondary bone healing?

. Absolute stability with anatomic reduction
. High-strain environment exceeding 10%
. High compression across a transverse fracture
. A large fracture gap with rigid fixation
. Moderate interfragmentary motion (relative stability)

Correct Answer & Explanation

. Absolute stability with anatomic reduction


Explanation

Intramedullary nailing of a comminuted diaphyseal fracture provides relative stability, which permits moderate interfragmentary motion (strain typically between 2% and 10%). This mechanical environment stimulates callus formation and secondary bone healing via enchondral ossification. Absolute stability (strain < 2%), provided by compression plating, leads to primary bone healing without visible callus.

Question 1595

Topic: Biology, Genetics & Bone Healing

During fracture healing by secondary intention, the transition from soft callus to hard callus is primarily driven by endochondral ossification. Which of the following transcription factors is most critical for the commitment of mesenchymal stem cells to the chondrogenic lineage during this physiological process?

. Runx2 (Cbfa1)
. Osterix (Sp7)
. Sox9
. NFATc1
. Beta-catenin

Correct Answer & Explanation

. Runx2 (Cbfa1)


Explanation

Sox9 is considered the master transcription factor for chondrogenesis and is absolutely required for the differentiation of mesenchymal stem cells into chondrocytes during endochondral ossification. Runx2 (Cbfa1) and Osterix (Sp7) are critical transcription factors for osteoblast differentiation. NFATc1 is an essential transcription factor for osteoclastogenesis. Beta-catenin is a key component of the Wnt signaling pathway, which promotes osteoblastic differentiation while simultaneously suppressing chondrogenesis.

Question 1596

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a lytic lesion in the distal femur extending to the subchondral bone. Biopsy reveals multinucleated giant cells interspersed in a background of neoplastic mononuclear stromal cells. She is treated preoperatively with Denosumab to downstage the tumor prior to curettage. What is the specific mechanism of action of this medication?

. It induces direct apoptosis of the multinucleated giant cells.
. It binds to the RANK receptor on osteoclasts, preventing their activation.
. It binds directly to RANK Ligand (RANKL), preventing its interaction with the RANK receptor.
. It acts as a competitive antagonist for the osteoprotegerin (OPG) pathway.
. It is a targeted tyrosine kinase inhibitor blocking the VEGF receptor.

Correct Answer & Explanation

. It induces direct apoptosis of the multinucleated giant cells.


Explanation

Denosumab is a fully human monoclonal antibody that specifically binds to and neutralizes RANK Ligand (RANKL). In Giant Cell Tumor of Bone (GCTB), the neoplastic mononuclear stromal cells overexpress RANKL. This overexpression recruits and activates normal multinucleated osteoclast-like giant cells via their RANK receptors, causing massive bone destruction. By binding to RANKL, denosumab prevents its interaction with the RANK receptor, thereby halting the formation, function, and survival of the destructive giant cells.

Question 1597

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with worsening chronic knee pain. Radiographs show an eccentric, purely lytic epiphyseal lesion in the distal femur without a sclerotic border. A core needle biopsy reveals numerous multinucleated giant cells interspersed among a background of mononuclear stromal cells. Due to the extensive size of the tumor and proximity to the joint line, she is prescribed a medication to induce a sclerotic rim prior to surgical curettage. This medication exerts its primary effect by binding to which of the following targets?

. RANK
. Macrophage colony-stimulating factor
. RANKL
. Osteoprotegerin
. Carbonic anhydrase II

Correct Answer & Explanation

. RANK


Explanation

Giant cell tumor of bone (GCT) is characterized by neoplastic mononuclear stromal cells that express RANKL, which recruits and activates benign multinucleated giant cells (osteoclast-like cells) to resorb bone. Denosumab is a fully human monoclonal antibody that specifically binds to RANKL, preventing it from activating RANK on the giant cells. This effectively halts osteolysis, allowing the bone to form a sclerotic rim around the tumor, which can facilitate surgical downstaging and curettage.

Question 1598

Topic: Biology, Genetics & Bone Healing

A 45-year-old man requires a structural allograft to manage a massive diaphyseal bone defect following tumor resection. He receives a massive cortical bone allograft. Following early hemorrhage, inflammation, and eventual revascularization, how does the initial cellular process of graft incorporation in this cortical bone segment fundamentally differ from that of cancellous bone graft?

. Direct intramembranous ossification by mesenchymal stem cells occurs first
. Osteoclasts resorb dead bone via cutting cones followed by osteoblastic new bone formation
. Osteoblasts form new bone on dead trabeculae followed by osteoclastic resorption
. Fibroblasts deposit type III collagen followed by remodeling into type I collagen
. Chondrocytes undergo hypertrophy followed by endochondral ossification

Correct Answer & Explanation

. Direct intramembranous ossification by mesenchymal stem cells occurs first


Explanation

Cortical bone grafts incorporate via a process called creeping substitution, heavily reliant on osteoclast function. Osteoclasts act at the head of a cutting cone to bore through and resorb necrotic cortical bone, followed closely by osteoblasts laying down new lamellar bone. In contrast, cancellous bone grafts incorporate primarily through initial appositional bone formation, where osteoblasts first lay down new woven bone on top of the dead scaffolding trabeculae before later remodeling by osteoclasts occurs.

Question 1599

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman is diagnosed with an aggressively expanding, recurrent giant cell tumor of the distal radius that is deemed unresectable without severe functional morbidity. The multidisciplinary tumor board recommends medical management with denosumab prior to potential further surgical intervention.

Denosumab affects the biology of this tumor by primarily binding to and inhibiting which of the following?

. Receptor activator of nuclear factor kappa-B (RANK)
. Receptor activator of nuclear factor kappa-B ligand (RANKL)
. Macrophage colony-stimulating factor (M-CSF)
. Osteoprotegerin (OPG)
. Vascular endothelial growth factor (VEGF)

Correct Answer & Explanation

. Receptor activator of nuclear factor kappa-B (RANK)


Explanation

Giant cell tumor of bone (GCT) is characterized by neoplastic mononuclear stromal cells that express high levels of RANKL. This RANKL binds to the RANK receptor on osteoclast precursors, driving the massive recruitment and activation of osteoclast-like multinucleated giant cells that cause bone destruction. Denosumab is a fully human monoclonal antibody that binds directly to RANKL (not RANK), preventing its interaction with RANK and thereby drastically reducing the numbers of destructive giant cells and halting osteolysis.

Question 1600

Topic: Biology, Genetics & Bone Healing

A 65-year-old man presents with severe back pain, generalized fatigue, and new-onset hypercalcemia. Skeletal survey reveals multiple 'punched-out' lytic lesions in the skull and vertebral bodies.

A bone marrow biopsy confirms multiple myeloma. The profound osteolytic bone disease in this patient is primarily mediated by myeloma cells upregulating osteoclast activity and inhibiting osteoblast differentiation through the secretion of factors including Dickkopf-1 (DKK1) and which of the following crucial cytokines?

. Bone morphogenetic protein 2 (BMP-2)
. Interleukin-6 (IL-6)
. Transforming growth factor-beta (TGF-b)
. Fibroblast growth factor 23 (FGF-23)
. Interferon-gamma (IFN-g)

Correct Answer & Explanation

. Bone morphogenetic protein 2 (BMP-2)


Explanation

In multiple myeloma, malignant plasma cells profoundly disrupt the bone marrow microenvironment. They secrete cytokines, most notably Interleukin-6 (IL-6) and Macrophage Inflammatory Protein-1 alpha (MIP-1a), which dramatically upregulate RANKL expression in stromal cells, leading to runaway osteoclast activation. Additionally, myeloma cells secrete Dickkopf-1 (DKK1), which acts as an inhibitor of the Wnt signaling pathway, thereby suppressing osteoblast differentiation. This dual mechanism causes pure lytic lesions without reactive bone formation.